Filing Details
- Accession Number:
- 0000950170-25-033766
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-05 16:48:35
- Reporting Period:
- 2025-03-03
- Filing Date:
- 2025-03-05
- Accepted Time:
- 2025-03-05 16:48:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1971543 | Mural Oncology Plc | MURA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1989488 | Caroline Loew | C/O Mural Oncology Plc 10 Earlsfort Terrace Dublin 2 L2 D02 T380 | Chief Executive Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2025-03-03 | 72,275 | $0.00 | 309,903 | No | 4 | A | Direct | |
| Ordinary Shares | Disposition | 2025-03-04 | 4,313 | $3.36 | 305,590 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Stock Option (right to buy) | Acquisiton | 2025-03-03 | 134,225 | $0.00 | 134,225 | $3.43 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 134,225 | 2035-03-02 | No | 4 | A | Direct |
Footnotes
- Consists of ordinary shares issuable under 72,275 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 3, 2025, subject to the reporting person's continued service with the Issuer.
- Includes 189,693 restricted stock units.
- Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 1, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on March 27, 2024, and the sale does not represent a discretionary trade by the Reporting Person.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- This option was granted on March 3, 2025. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 3, 2026 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued services with the Issuer.
Billionaire Hedge Funds
